Short Interest in Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Grows By 20.9%

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) saw a large growth in short interest in the month of December. As of December 31st, there was short interest totaling 223,283 shares, a growth of 20.9% from the December 15th total of 184,642 shares. Approximately 3.8% of the company’s stock are short sold. Based on an average daily trading volume, of 230,112 shares, the short-interest ratio is currently 1.0 days. Based on an average daily trading volume, of 230,112 shares, the short-interest ratio is currently 1.0 days. Approximately 3.8% of the company’s stock are short sold.

Salarius Pharmaceuticals Stock Performance

Shares of Salarius Pharmaceuticals stock traded up $0.19 during midday trading on Monday, reaching $0.84. 5,993,436 shares of the company’s stock traded hands, compared to its average volume of 619,609. Salarius Pharmaceuticals has a 52 week low of $0.51 and a 52 week high of $108.00. The company’s 50 day simple moving average is $0.83 and its 200 day simple moving average is $4.58. The company has a market cap of $4.89 million, a price-to-earnings ratio of -0.02 and a beta of 0.33.

Salarius Pharmaceuticals (NASDAQ:SLRX) last issued its quarterly earnings data on Friday, November 14th. The company reported ($1.81) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($33.60) by $31.79.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on SLRX shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Salarius Pharmaceuticals in a research note on Monday, December 29th. Wall Street Zen lowered Salarius Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, January 3rd. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has an average rating of “Sell”.

About Salarius Pharmaceuticals

Salarius Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that target epigenetic and post‐translational modification pathways in cancer. The company’s lead candidate, seclidemstat (SP‐2577), is designed to inhibit lysine‐specific demethylase 1 (LSD1) and modulate the tumor microenvironment, with a primary focus on treating Ewing sarcoma, a rare and aggressive bone and soft tissue cancer affecting children and young adults.